National Psoriasis Foundation Medical Board and the International Psoriasis Council
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors
This guideline holds 1 recommendation and 1 table.
Summary
Although testing for latent tuberculosis (TB) infection has been standard practice for psoriasis patients being treated with interleukin (IL) 17 or IL-23 inhibitors, evidence for this practice is weak.
Key takeaways
Clinical data suggest that progression of latent tuberculosis infection to active disease during psoriasis treatment with interleukin-17 or interleukin-23 inhibitors is rare.
Experts formulated a new Joint Position Statement, highlighting that testing for latent tuberculosis infection is not required in psoriasis patients being treated with interleukin-17 or interleukin-23 inhibitors.